These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Pharmacokinetic analysis of Neoral conversion in pediatric and adult renal transplant recipients with poor absorption of Sandimmune. Pescovitz MD; Henson S; Bodziak K; Book BK; Gonin J; Jindal RM; Leapman SB; Milgrom ML; Filo RS Transplant Proc; 1996 Aug; 28(4):2165-8. PubMed ID: 8769189 [No Abstract] [Full Text] [Related]
30. Cyclosporine pharmacokinetics in renal allograft recipients with diabetes mellitus with Sandimmune and Sandimmune Neoral. Serafinowicz A; Gaciong Z; Baçzkowska T; Durlik M; Lao M Transplant Proc; 1996 Dec; 28(6):3140-1. PubMed ID: 8962217 [No Abstract] [Full Text] [Related]
31. Pharmacokinetic considerations in the therapeutic application of cyclosporine in renal transplantation. Kahan BD Transplant Proc; 1996 Aug; 28(4):2143-6. PubMed ID: 8769182 [No Abstract] [Full Text] [Related]
32. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Olbricht C; Wanner C; Eisenhauer T; Kliem V; Doll R; Boddaert M; O'Grady P; Krekler M; Mangold B; Christians U Clin Pharmacol Ther; 1997 Sep; 62(3):311-21. PubMed ID: 9333107 [TBL] [Abstract][Full Text] [Related]
33. Comparison of pharmacokinetics between CsA capsules and Sandimmun Neoral in pediatric patients. Lin CY; Lee SF Transplant Proc; 1994 Oct; 26(5):2973-4. PubMed ID: 7940938 [No Abstract] [Full Text] [Related]
34. Pharmacoeconomics of Neoral, a new formulation of cyclosporine, in renal transplantation. Abella I Transplant Proc; 1996 Dec; 28(6):3131-4. PubMed ID: 8962213 [No Abstract] [Full Text] [Related]
35. Excessive cyclosporine trough level variation with classic cyclosporine can be reduced with the new oral microemulsion formulation of cyclosporine. Bökenkamp A; Offner G; Hoyer PF; Wonigeit K; Brodehl J Transplant Proc; 1996 Aug; 28(4):2273-5. PubMed ID: 8769223 [No Abstract] [Full Text] [Related]
36. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients? Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945 [TBL] [Abstract][Full Text] [Related]
37. A randomized, controlled trial to assess the safety of switching stable renal transplant patients from Sandimmun to Sandimmun Neoral. Loo CS; Morad Z; Lim TO; Fan KS; Suleiman AB Transplant Proc; 1996 Jun; 28(3):1328-9. PubMed ID: 8658680 [No Abstract] [Full Text] [Related]
38. The pharmacokinetics of Sandimmun Neoral: a new oral formulation of cyclosporine. Holt DW; Mueller EA; Kovarik JM; van Bree JB; Kutz K Transplant Proc; 1994 Oct; 26(5):2935-9. PubMed ID: 7940927 [No Abstract] [Full Text] [Related]
39. Experience with clinical use of Sandimmun Neoral in renal transplant patients. Min ZL; Zhao M; Zhu YH; Qi J; Wang LM; Wang YW Transplant Proc; 1996 Jun; 28(3):1356-7. PubMed ID: 8658692 [No Abstract] [Full Text] [Related]
40. Safety and tolerability of CyA microemulsion formulation (Sandimmun Neoral) in stable renal transplant patients after 24 months of treatment. German Neoral Study Group. Offermann G; Korn A Transplant Proc; 1996 Aug; 28(4):2204-6. PubMed ID: 8769201 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]